Fig. 9

NORAD silencing repressed tumor growth through the miR-495-3p/TRIP13 axis in vivo. a, b The expression levels of NORAD and miR-495-3p in LNCaP cells transfected with sh-NC, sh-NORAD, or sh-NORAD + anti-miR-495-3p were detected with qRT-PCR. c Tumor volume was measured once a week in mice of the sh-NC, sh-NORAD, or sh-NORAD + anti-miR-495-3p groups. d A graph showing the tumor size of mice. e Tumor weight of mice of the sh-NC, sh-NORAD, or sh-NORAD + anti-miR-495-3p groups was assessed on day 35. f–h The expression of NORAD, miR-495-3p, and TRIP13 mRNA in tumor tissues of mice of the sh-NC, sh-NORAD, or sh-NORAD + anti-miR-495-3p groups was examined by qRT-PCR. i, j The levels of TRIP13 prtoein, cyclin D1, and PCNA in mice tumor tissues of the sh-NC, sh-NORAD, or sh-NORAD + anti-miR-495-3p groups were detected through western blot analysis. **P < 0.01 and ***P < 0.001